Justin Chakma is Chief Business Officer at ARS Pharmaceuticals, Inc. (SPRY). They have made 6 open-market trades across 1 company since 2024, most recently 2025-11-12.
CIK 0001951238
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SPRY | 166,380 | $667K |
Shares reported on the most recent Form 4, priced at the 2025-11-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRY | SELL | 2025-11-12 | 2025-11-14 | $8.86 | $2.7M | +18.1% | +30.7% | +8.8% |
| SPRY | SELL | 2024-12-12 | 2024-12-13 | $12.23 | $3.5M | -6.6% | -5.7% | +0.1% |
| SPRY | SELL | 2024-12-10 | 2024-12-12 | $13.15 | $658K | -9.9% | -11.1% | -2.8% |
| SPRY | SELL | 2024-12-04 | 2024-12-06 | $14.11 | $2.7M | -21.8% | -20.9% | -23.0% |
| SPRY | SELL | 2024-12-02 | 2024-12-04 | $13.43 | $1.2M | -17.4% | -22.2% | -27.0% |
| SPRY | SELL | 2024-11-25 | 2024-11-27 | $14.10 | $2.0M | -10.8% | -25.7% | -27.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.